Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 0.63 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30503085 | 1.00 | PIK3CA (0.63) | PIK3CAPIK3R1 | |
| SCHEMBL25402946 | 0.96 | PIK3CA (0.60) | PIK3CAPIK3R1 | |
| SCHEMBL30503099 | 0.96 | PIK3CA (0.60) | PIK3CAPIK3R1 | |
| SCHEMBL30448143 | 0.90 | PIK3CA (0.53) | PIK3CAPIK3R1 | |
| SCHEMBL25251216 | 0.90 | PIK3CA (0.53) | PIK3CAPIK3R1 | |
| SCHEMBL25404322 | 0.90 | PIK3CA (0.54) | PIK3CAPIK3R1 | |
| SCHEMBL30503084 | 0.90 | PIK3CA (0.54) | PIK3CAPIK3R1 | |
| SCHEMBL25220236 | 0.90 | PIK3CA (0.57) | PIK3CAPIK3R1 | |
| SCHEMBL30446518 | 0.90 | PIK3CA (0.57) | PIK3CAPIK3R1 | |
| SCHEMBL25273365 | 0.88 | PIK3CA (0.59) | PIK3CAPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271965-A1 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | YUMANITY THERAPEUTICS, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230271965-A1 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | YUMANITY THERAPEUTICS, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230271965-A1 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | YUMANITY THERAPEUTICS, INC. | 2023-08-31 | — | — | US | disclosed |
| WO-2023107623-A2 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271965-A1 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | NLN, GRIN2C, BCHE | PIK3CA 4620/4885PIK3R1 4349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.